Objective: Secondary prevention in patients with critical limb ischemia (CLI) is crucial for the reduction of cardiovascular morbidity and mortality. Nonetheless, current recommendations are extrapolated from other high-risk populations because of the lack of CLI-dedicated trials. The aim of this explorative study was to evaluate the association of statin therapy with the outcomes of CLI patients.
Only a minority of medical conditions and biochemical pathways have been subjected to such excessive research as the essential role of cholesterol-carrying low-density lipoprotein (LDL) in the development of atherosclerotic disease. 1 Since the development of the first hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) in the late 1970s, a large number of observational studies and randomized controlled trials indicated a consistent reduction in major adverse cardiovascular and cerebral events (MACCEs) from statin therapy. 2, 3 Based on this large body of evidence, lipid-lowering therapy with statins is recommended in secondary prevention for patients with manifested atherosclerotic disease. 3 On the other hand, not all high-risk populations for cardiovascular events benefit from statin therapy, implying that the severity and the form of atherosclerotic disease or the specific characteristics of each subgroup may influence the cardioprotective effect of these agents. 3, 4 Concerning peripheral arterial disease (PAD), the updated report of the American College of Cardiology and American Heart Association suggested the abolition konstantinos@yahoo.gr).
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Copyright of LDL targets in favor of specific statin regimens that produce a 30% to 50% reduction in LDL. 3, 5 Other recommendations suggest a lipid-lowering therapy in all patients with PAD to achieve a target LDL of <100 mg/dL or 70 mg/dL for patients at very high risk of ischemic events. 6, 7 The aim of the treatment is to reduce the markedly increased cardiovascular morbidity and mortality while increasing the limb salvage rates. 8 Of note, current recommendations do not differentiate between patients with intermittent claudication and subjects with critical limb ischemia (CLI). 3, [5] [6] [7] However, the effect of statin therapy in CLI patients remains understudied. Available data are derived from studies analyzing both intermittent claudication and CLI patients, retrospective or single-center studies, and studies evaluating only one treatment option, namely, endovascular or surgical approach. [9] [10] [11] [12] Moreover, the role of secondary prevention in limb salvage and specific limb events is still unclear.
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The First-Line Treatments in Patients With Critical Limb Ischemia (CRITISCH) registry aimed to evaluate the performance of all first-line treatment strategies applied in unselected CLI patients. [14] [15] [16] The aim of this report was to evaluate the association between statin therapy and the hazard of amputation and death by univariate and multivariable statistical analyses of data from the CRIT-ISCH registry.
METHODS
Study design. The CRITISCH study was conducted in compliance with the Declaration of Helsinki. Ethical approval was obtained from all local ethics committees of the participating centers before the recruitment phase, and all patients provided written informed consent.
Full details of study design, protocols, and methods have been previously reported and are briefly summarized here. 15, 16 CRITISCH is a prospective, interdisciplinary, multicenter registry evaluating the current practice of all available treatment options in unselected CLI patients treated in 27 German vascular centers. The inclusion criterion was the presence of new-onset CLI. CLI was defined as an ankle-brachial index <0.40 or ischemic rest pain, or both, with or without tissue loss in the presence of PAD (Rutherford classes 4-6). Only one limb per patient could be included. Exclusion criteria were acute limb ischemia, isolated aortoiliac interventions, vascular trauma, and known clotting or nonatherosclerotic vascular disorders. Between January 2013 and September 2014, 1200 patients were enrolled. Follow-up visits were planned at 6, 12, and 24 months. The registry was validated by an external audit at participating centers to monitor the accuracy of protocol documentation. Type of revascularization strategy and medication were left to the discretion of the treating physician. There was no restriction concerning the selected treatment option. The administration of the patients' statin, antiplatelet, or oral anticoagulation agents was recorded by protocol at entry into the study and at every follow-up visit. Medication use was self-reported by the patients and was compared with baseline data and the prescribed medication of the treating general practitioner to determine treatment adherence. Only patients who received statins continuously (statin group) and patients who never received statins during follow-up (no-statin group) were considered. Treatment crossovers and nonadherent patients were excluded from all analyses because they could not be allocated to any group in a reasonable manner.
End points. The primary composite end point of the CRITISCH registry was amputation-free survival (AFS), defined as the time until a major amputation of the index limb or death of any cause, whichever occurred first. Major amputation was defined as any above-ankle amputation. The odds of MACCEs (defined as the event of acute coronary syndrome, stroke, or death), the time to death, and the time to major amputation were also analyzed. All patient-individual event times were censored at the last date of contact, given that the patient was still event free at this date. The time to major amputation was also censored at the date of death, given that the patient had not received a major amputation before.
Statistical analysis. All statistical computations were carried out using R 3. The authors recommend that statins be prescribed and monitored for use in critical limb ischemia patients to increase amputation-free survival and to reduce mortality and cardiovascular events. and log-rank tests. Multivariable Cox regression models of time-to-event end points were created to obtain covariate-adjusted estimates of hazard ratios (HRs) with corresponding Wald-type CIs. All demographic and clinical parameters from Table I were considered as possible covariates. Model building was done by all-subset variable selection using the Akaike information criterion to find the best model among all possible candidate models that include the statin group as covariate. In the same way, a multivariable logistic regression model was built for the end point MACCE at 1 year to obtain covariate-adjusted estimates of odds ratios (OR) and referring Wald-type CIs.
RESULTS
Patients' characteristics. Statin therapy was applied to 681 (57%) of the 1200 patients at baseline. Discontinuation of statin treatment was observed in 236 of these patients, whereas 118 patients not receiving statins at baseline crossed over into the statin group during follow-up. Thus, the statin and no-statin groups consisted of 445 (37%) and 371 (31%) patients, whereas 384 subjects (32%) were excluded from this analysis because of treatment crossover.
Endovascular therapy was the treatment of choice in both groups (statin, 52%; no-statin, 60%), followed by bypass surgery (statin, 26%; no-statin, 20%), common or deep femoral artery revascularization (statin, 12%; no-statin, 11%), and conservative treatment (statin, 9%; no-statin, 10%; Table I ). Patients prescribed statins were more likely to be younger (P < .001) and to have a history of coronary heart disease (CHD; P < .001), previous acute coronary syndrome (P ¼ .033), or previous vascular intervention at the index limb (P < .001). Moreover, patients receiving statin therapy presented more frequently with ischemic rest pain (Rutherford class 4), and patients not receiving statins presented more frequently with ulcerations of the digits or the foot (Rutherford class 5; P < .001). Patients receiving statins also had lower modified Edifoligide for the Prevention of Vein Graft Failure in Lower Extremity Bypass SurgerydPhase III Trial (PREVENT III) risk scores (P < .001) and were less likely to have a chronic kidney disease (CKD; P ¼ .047) at baseline. Antiplatelet agents were more frequently used among patients receiving statin therapy (86% vs 65%; P < .001; Table I ).
End points. The Fig presents the Kaplan-Meier estimates of AFS, OS, and AF time for both groups. Log-rank tests indicate that statin therapy was associated with an increased AFS (P < .001) and increased OS (P < .001) without improving the AF time (P ¼ .482). Because of the lack of randomization, Cox regression models of AFS, OS, and AF time were built (Table II) to obtain covariate-adjusted HR. Again, statin treatment was associated with an increased AFS (HR, 0.45; 95% CI, 0.34-0.63; P < .001) and OS (HR, 0.40; 95% CI, 0.24-0.66; P < .001), but a noticeable association with AF time was not observed (HR, 1.02; 95% CI, 0.67-1.56; P ¼ .922). Furthermore, multivariate logistic regression (Table III) revealed lower odds for MACCEs at 1 year among patients receiving statin (OR, 0.41; 95% CI, 0.23-0.69; P ¼ .001). The multivariable Cox and logistic regression models were also stratified by study centers (centers with only a few patients were merged to one stratum). The resulting HRs and ORs were similar to those stated before and therefore not presented here. 
DISCUSSION
Despite the growing prevalence of lower extremity atherosclerosis and the related high cardiovascular morbidity and mortality, PAD remains an underdiagnosed and undertreated disease. 8, 17 Although PAD is identified as a CHD risk equivalent, patients with peripheral atherosclerosis have significantly less chance of receiving an appropriate risk factor modification than patients with CHD because of the current failure of many physicians to recognize the associated increased cardiovascular risk. 9, [18] [19] [20] In addition, in contrast to CHD, the lack of large randomized controlled trials led to paucity of PAD-specific evidence. 18 In regard to CLI, the effect of secondary prevention strategies remains unclear, and current recommendations are adopted from other high-risk populations. 13 An improved AFS was observed in this study among unselected CLI patients receiving statin therapy.
Interestingly, the selected first-line treatment did not influence this finding, as higher AFS rate was observed in the statin group after both endovascular and surgical revascularization. In line with our observations, in many single-center or retrospective studies, a higher AFS was observed among CLI patients prescribed statin medications at baseline. 9, [21] [22] [23] However, in the majority of the published series, the authors could not provide any data concerning discontinuation of statin therapy or Results were obtained by a multivariable logistic regression model. Model building was done by all-subset variable selection based on the Akaike information criterion. All demographic and clinical parameters from Table I were considered as possible covariates for bias adjustment.
noncompliance. In addition, in a subgroup analysis of the Reduction of Atherothrombosis for Continued Health (REACH) registry evaluating both claudicants and CLI patients, subjects who were not taking statins demonstrated a higher risk for the composite end point of cardiovascular death, nonfatal acute coronary syndrome, or nonfatal stroke. 10 Notably, statins were associated with improved AFS not only in patients taking antiplatelet agents but also in patients not receiving antiplatelet medication as well.
On the other hand, although improved AFS and OS rates were observed among patients receiving statin therapy, patients taking statins did not show higher limb salvage rates. Despite the fact that statins are associated with improved patency after surgical and endovascular procedures, the role of secondary prevention in limb salvage is a matter of debate. 13, 24, 25 A significant reduction of limb-specific events was observed in studies assessing patients with CLI and claudication; however, a number of CLI-specific studies failed to show a similar benefit in regard to major amputation rates. 9, 10, 21, 22, [26] [27] [28] We assume that the high burden of peripheral atherosclerosis found in CLI may limit the impact of statins observed in the coronaries. Moreover, this finding implies the necessity of CLI-dedicated trials, given the different needs and prognosis of claudicants and CLI patients. An important finding of the current analysis is the potential beneficial role of statins in challenging CLI subgroups, namely, patients with diabetes, patients with CKD, and individuals older than 75 years. Despite the well-described favorable prognosis of nonhemodialysis-dependent CKD patients taking statins, the role of lipid-lowering therapy in coexisting CLI and CKD is unknown. 29 Although CKD is an important determinant of cardiovascular morbidity and mortality in CLI, in many studies, the presence of renal function impairment was an exclusion criterion. Concerning older patients, a large body of evidence supports the use of statins in the secondary prevention of clinical cardiovascular disease. 3 Conte et al reported also a 3.1 times higher risk for a perioperative adverse event in patients older than 75 years not receiving lipid-lowering medication. 30 On the other hand, there are some concerns about statin therapy. Discontinuation of statin administration remains a common problem, especially in highintensity regimens. [31] [32] [33] Statin-associated muscle syndromes likely contribute to lower adherence rates, although the frequency of excessive rhabdomyolysis is rare. [34] [35] [36] In our study, 34% of patients receiving statins at baseline discontinued their therapy during follow-up. Administration of proprotein convertase subtilisin/kexin type 9 inhibitors or other lipid-lowering agents could be a safe alternative in patients experiencing statinrelated adverse events; however, the impact of these therapies in CLI patients is not determined. 37 Furthermore, statins modestly increase the risk for new-onset type 2 diabetes; however, this finding does not outweigh the beneficial effect of statin therapy in patients at high risk for cardiovascular complications. 3 Finally, despite the significance of secondary prevention, there are still many areas of uncertainty regarding lipid-lowering therapy in CLI patients. For example although the abolition of LDL-specific targets in favor of specific statin regimens was suggested, concerns were raised about the effectiveness of this strategy. 38 Another important issue is the uncertainty of the cardioprotective statin effect in patients with coexisting CLI and end-stage renal disease.
LIMITATIONS
Several aspects of this analysis warrant comment. Notwithstanding the well-known limitations of registries, the CRITISCH registry was not designed to examine the association of lipid-lowering therapy with specific clinical outcomes. There was no randomization between the two groups of patients, although a randomized controlled trial would be unethical, given the current recommendations for a statin therapy in PAD patients. In addition, statin use is analyzed as a binary variable because we cannot provide any data concerning statin type and statin dose. However, the CRITISCH registry was designed and started to enroll patients before the publication of the updated American Heart Association guidelines, which changed the approach to lipidlowering therapies. 3 Thus, we did not focus our research design on the dose of statins. Duration of statin therapy before study enrollment, prescription of other lipid-lowering medications, and lipid values were also not documented. Because there was no reasonable way to allocate treatment crossovers and nonadherent patients to either the statin or no-statin group, these patients were excluded from our analysis. Hence, the estimated effects of statin use are likely to be higher than in real practice, in which noncompliance is normality. The rate of statin intolerance and the reason for nonadherence among patients not receiving statins are unknown. However, lack of efficacy represents an uncommon reason for nonadherence as statin discontinuation is mainly associated with muscle-related symptoms. 39 
CONCLUSIONS
Although lipid-lowering therapy with statins has been among the most well studied pharmacologic therapies, the effect of these agents in CLI patients remains not well determined. Collectively, our findings suggest that statin therapy in CLI patients is associated with increased AFS and lower rates of mortality and MACCEs regardless of the applied treatment strategy. In contrast, we found no indication that statin therapy influences the fate of the affected limb. Further research is needed to assess areas of uncertainty in the secondary prophylaxis of CLI individuals.
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